The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

A drug for treating diabetes similar to popular weight-loss medicines such as Ozempic did not show any benefits for people ...

Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...

After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

They're known to aid in blood sugar control and, now, weight loss — but, according to a sweeping new study, the popular GLP-1 ...

Prescriptions of obesity management drugs (OMDs) have increased, and these increasing trends are associated with online ...

HMB is produced naturally in our bodies during the metabolism of the essential amino acid leucine. While many of HMB’s ...